August 27, 2026

To,
The Listing Compliance Department
BSE Limited
P. J. Towers, Dalal Street
Mumbai – 400001
Scrip Code: 524632

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Symbol: SHUKRAPHAR

Dear Sir/Madam,

Sub.: Intimation of Postal Ballot Notice of the Company

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the Postal Ballot Notice dated August 22, 2026.

Further the Postal Ballot Notice sent only through electronic mode to those Members who have registered their e-mail address with their Depository Participant(s) ('DPs') or with the Registrar and Share Transfer Agent of the Company and whose names appear in the Register of Members/ List of Beneficial Owners as received from Depositories i.e. National Securities Depository Limited ('NSDL')/Central Depository Services (India) Limited ('CDSL') and for reckoning the voting rights of the Members of the Company as on Friday, 21st August, 2026. ('Cut-off date') in accordance with the provisions of the Companies Act, 2013, read with Rules made thereunder and applicable MCA Circulars and SEBI Circulars.

The Company has availed remote e-voting facility from NSDL and below is the calendar of the events for remote e-voting:

1.	Date of completion of dispatch of notice of postal ballot to the shareholders of the Company through E-mail	August 27, 2026
2.	Cut-off date to record the entitlement of the shareholders to cast their vote electronically.	August 21, 2026
3.	Date and time of commencement of voting through electronic means and physical ballot form	August 28, 2026 at 09.00 A.M. (IST)
4.	Date and time of end of voting through electronic means and last date for receipt for physical ballot form	September 26, 2026 at 05.00 P.M. (IST).
5.	Date of declaration of result by the Chairman /Company Secretary on or before	September 29, 2026

You are requested to consider the same for your reference and record.

The said information is also being made available on the website of the Company i.e www.shukrapharmaceuticals.com.

Thanking You
Yours faithfully
For Shukra Pharmaceuticals Limited

Shivkant Dhakad
Company Secretary
Membership No. A80894

SHUKRA

POSTAL BALLOT NOTICE

[Pursuant to Section 110 of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014]

Dear Member(s),

NOTICE is hereby given to the members of **Shukra Pharmaceuticals Ltd** (the "Company") that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) (the "**Act**") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 (the "**Rules**"), Circular Nos. 14/2020 dated April 08, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 20, 2020, 22/2020 dated June 15, 2020, 33/2020 dated September 28, 2020, 39/2020 dated December 31, 2020, 10/2021 dated June 23, 2021, 20/2021 dated December 08, 2021, 03/2022 dated May 05, 2022,11/2022 dated December 28, 2022 and 09/2023 dated September 25, 2023, 03/2025, dated September 22, 2025 issued by the Ministry of Corporate Affairs ("**MCA**") (hereinafter collectively referred to as "**MCA Circulars**"), Regulation 44 and other applicable provisions, if any of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("**Listing Regulations**"), read with applicable circulars under the Act and Listing Regulations, Secretarial Standard on General Meetings ('**SS-2**') issued by the Institute of Company Secretaries of India, the Articles of Association of the Company and subject to other applicable laws, rules and regulations, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), for seeking approval of the shareholders of the Company for the business set out hereunder through Postal Ballot ("**the Postal Ballot**") by way of remote e-voting ("**e-voting**") process.

An Explanatory Statement pursuant to Section 102 of the Act and other applicable provisions, pertaining to the below appended resolution setting out the material facts and the reasons thereof, is annexed herewith for your consideration.

In compliance with Regulation 44 of the Listing Regulations and pursuant to the provisions of Sections 108 and 110 of the Act read with the rules framed thereunder and the MCA Circulars, the manner of voting on the proposed resolution is restricted only to e-voting i.e., by casting votes electronically instead of submitting postal ballot forms. The postal ballot notice and instructions for e-voting are being sent only through electronic mode to those Members whose email address is registered with the Company / depository participant(s). The details of the procedure to cast the vote forms part of the 'Notes' to this Notice.

In compliance with Rule 22(5) of the Rules, the Board has appointed **Mrs. Rupal Patel** (FCS-6275, CP No-3803), Practicing Company Secretaries, Ahmedabad, as '**Scrutinizer**' to scrutinize the Postal Ballot process in a fair and transparent manner. She has communicated her willingness to be appointed and will be available for the said purpose.

In compliance with the provisions of Section 108 and 110 of the Act read with Rule 20 and 22 of the Rules, Regulation 44 of the Listing Regulations, and SS-2, the Company is pleased to provide e-voting facility to its Members, to enable them to cast their votes electronically. The detailed procedure with respect to e-voting is mentioned in this Notice.

The Company has engaged the services of National Securities Depository Limited ("**NSDL**") for facilitating e-voting. The Company has made necessary arrangements with Purva Sharegistry (India)

Private Limited, Registrar and Share Transfer Agent ("**RTA**") to enable the Members to register their e-mail address. Those Members who have not yet registered their e-mail address are requested to register the same by following the procedure set out in this Postal Ballot Notice.

The members desiring to exercise their vote on the resolutions included in this notice of the Postal Ballot by electronic means i.e. through e-voting services provided by NSDL. The e-voting period shall commence on **Friday, 28th August, 2026 at 9.00 am and end on Saturday, 26th September, 2026 at 5.00 pm**. Members are requested to carefully read the instructions given in this Postal Ballot Notice and record their assent (FOR) or dissent (AGAINST) through the e- voting process not later than **Saturday, 26th September, 2026**. E-voting will be blocked by NSDL immediately thereafter and voting will not be allowed beyond the said date and time.

Upon the completion of scrutiny of the votes, the Scrutinizer will submit her report to the to the Chairman or any other person authorized by the Chairman and the result of the voting by Postal Ballot will be announced not later than two (2) working days or three (3) days, whichever is earlier from the conclusion of the e-voting. The result declared along with the Scrutinizer's report shall be communicated in the manner provided in this Postal Ballot Notice.

The results of the Postal Ballot will be intimated to the BSE Limited and NSE Limited, where the shares of the Company are listed. The said results along with the Scrutinizer's Report will also be displayed on the website of the Company (www.shukrapharmaceuticals.com) as well as on NSDL's website- www.evoting.nsdl.com and will be displayed on the notice board of the Company at its Registered Office. In accordance with Secretarial Standards issued by the Institute of Company Secretaries of India and notified by the Central Government, the resolutions, if passed by requisite majority, shall be deemed to have been passed on the last date of voting i.e. **Saturday, 26th September, 2026.**

RESOLUTION FOR APPROVAL THROUGH POSTAL BALLOT

SPECIAL BUSINESSES:

1. **AMENDMENT IN OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY:**

   To consider and if thought fit, to pass, with or without modification(s), the following resolution as a ***Special Resolution****:*

   "RESOLVED THAT pursuant to the provisions of Sections 4, 13, 110 and other applicable provisions, if any, of the Companies Act, 2013 ("Act"), read with the rules made thereunder, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and subject to such approvals, consents, permissions and sanctions as may be required from the Registrar of Companies and/or any other statutory or regulatory authority, the consent of the Members of the Company be and is hereby accorded to alter the Objects Clause of the Memorandum of Association of the Company, by inserting the following new sub-clauses (2) to (6) after the existing sub-clause (1) under Clause III(A) – Objects to be pursued by the Company on its incorporation:

   (2) To carry on the business of research, innovation, design, development, engineering, manufacturing, assembling, fabrication, processing, testing, validation, installation, commissioning, licensing and commercialisation of medical devices, medical equipment, diagnostic systems, surgical instruments, surgical robotic systems, implantable devices,

wearable healthcare devices, artificial intelligence-based healthcare technologies, healthcare software, digital health platforms, telemedicine systems, hospital automation solutions and other healthcare and MedTech products and solutions.

(3) To act as manufacturers, buyers, sellers, importers, exporters, distributors, stockists, wholesalers, retailers, agents, representatives, licensors, franchisees and dealers in all kinds of medical technology products, healthcare devices, diagnostic equipment, robotic surgery systems, AI-driven healthcare solutions, laboratory equipment, hospital consumables, rehabilitation devices, healthcare software and allied products in India and abroad.

(4) To enter into strategic alliances, collaborations, technical partnerships, joint ventures, licensing arrangements, technology transfer agreements, franchise arrangements and Original Equipment Manufacturer (OEM) agreements with Indian and foreign companies, institutions, research organisations, hospitals, universities and governments for co-development, manufacturing, marketing, maintenance and commercialisation of healthcare and medical technology products and services.

(5) To establish, acquire, develop, construct, operate, maintain, lease, manage and promote Medical Technology Parks, healthcare industrial clusters, research laboratories, incubation centres, innovation hubs, manufacturing units, clean-room facilities, testing centres, warehouses and allied infrastructure for the promotion and growth of healthcare technology and medical device industries.

(6) To provide installation, commissioning, maintenance, repair, calibration, validation, technical support, consulting, training, certification, educational programmes and skill development services relating to medical devices, robotic surgical systems, healthcare software, digital healthcare technologies and other MedTech products for hospitals, clinics, healthcare professionals, distributors, institutions and government agencies.

(7) To develop, acquire, license, market, maintain and operate healthcare software, artificial intelligence systems, machine learning applications, cloud-based healthcare platforms, electronic medical record systems, hospital information systems, remote monitoring systems, cybersecurity solutions for healthcare and other digital healthcare technologies and services.

RESOLVED FURTHER THAT the existing sub-clause (1) under Clause III(A) of the Memorandum of Association shall continue to remain unchanged and the aforesaid sub-clauses (2) to (7) shall be inserted thereafter.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to make such modifications, alterations, additions, deletions or amendments to the aforesaid object clause as may be required by the Registrar of Companies, Ministry of Corporate Affairs, or any other statutory or regulatory authority, provided that such modifications do not materially alter the substance of the objects approved by the Members.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary of the Company, be and is hereby severally authorised to do all such acts, deeds, matters and things and to sign, execute and file all such applications, forms, documents, declarations and returns, including the requisite e-forms with the Registrar of Companies, Ministry of Corporate Affairs, and to make such filings, submissions and representations as may be necessary, proper or expedient to give effect to this resolution**.”**

2. **CHANGE OF NAME OF THE COMPANY FROM ‘SHUKRA PHARMACEUTICALS LIMITED’ to ‘SHUKRA MEDTECH LIMITED’ AND CONSEQUENT AMENDMENT IN MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY:**

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 4, 13, 14 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”), read with the Companies (Incorporation) Rules, 2014 and other rules made thereunder, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and subject to such approvals, consents, permissions and sanctions as may be required from the Registrar of Companies, Ministry of Corporate Affairs and/or any other statutory, regulatory or governmental authority, the consent of the Members of the Company be and is hereby accorded for changing the name of the Company from **“SHUKRA PHARMACEUTICALS LIMITED”** to **“SHUKRA MEDTECH LIMITED”**.

RESOLVED FURTHER THAT upon the new name of the Company being approved and made effective in accordance with applicable law, the existing Clause I of the Memorandum of Association of the Company relating to the name of the Company be and is hereby altered and substituted with the following:

“I. The name of the Company is ‘SHUKRA MEDTECH LIMITED’.”

RESOLVED FURTHER THAT pursuant to the provisions of Section 14 and other applicable provisions of the Companies Act, 2013, the Articles of Association of the Company be and are hereby altered by substituting the existing name of the Company, wherever appearing therein, with the new name **“SHUKRA MEDTECH LIMITED”**, upon the change of name becoming effective.

RESOLVED FURTHER THAT the change of name of the Company shall not affect any rights, obligations, liabilities, contracts, agreements, proceedings or other legal matters of or against the Company and all such rights, obligations, liabilities, contracts, agreements, proceedings and matters shall continue in the name of the Company as so altered.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary, be and is hereby severally authorised to make the necessary application(s), submit the requisite documents and obtain all necessary approvals, permissions, consents and confirmations in connection with the proposed change of name of the Company and to file the requisite forms, returns and documents with the Registrar of Companies, Ministry of Corporate Affairs and/or any other statutory, regulatory or governmental authority, as may be required.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary, be and is hereby severally authorised to make such modifications, alterations, additions or amendments to the aforesaid resolution, Memorandum of Association and Articles of Association as may be required by the Registrar of Companies, Ministry of Corporate Affairs or any other competent authority, provided that such modifications are in connection with and do not materially alter the substance of the change of name approved by the Members.

RESOLVED FURTHER THAT any Director of the Company or the Company Secretary, be and is hereby severally authorised to do all such acts, deeds, matters and things, execute all such documents, applications, declarations and writings and take all such steps as may be necessary, proper, expedient or desirable for giving effect to this resolution and for matters connected therewith or incidental thereto."

Date: 22/08/2026
Place: Ahmedabad

By the order of the Board
For Shukra Pharmaceuticals Limited

Sd/-
Dakshesh Shah
Chairman & Managing Director
DIN: 00561666

Registered office:
3rd Floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, 380054
CIN: L24231-GJ1993PLC019079
E-mail: info@shukrapharmaceuticals.com
Website: www.shukrapharmaceuticals.com

NOTES:

1. **An explanatory statement pursuant to Section 102 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014, setting out the material facts concerning the Special Resolution and the reasons thereof is annexed.**
2. In compliance with the MCA Circulars, the Company is sending this Postal Ballot Notice to the Members in electronic form only. Accordingly, the communication of the assent or dissent of the Members would take place through e-voting only.
3. The Postal Ballot Notice is being sent to the Member(s) whose names appear on the Register of Members/List of Beneficial Owners as received from the National Securities Depository Limited ("**NSDL**") and Central Depository Services (India) Limited ("**CDSL**") as **on Friday, 21st August, 2026**. The Postal Ballot Notice is being sent to the Members who have registered their email IDs for receipt of documents in electronic form to their email addresses registered with their Depository Participants/the Company's Registrar and Share Transfer Agent ("**RTA**").
4. Member(s) whose names appear on the Register of Members/List of Beneficial Owners as on the cut-off date will be considered for the purpose of voting/e-voting. A person who is not a member as on the cut-off date should treat this Notice for information purpose only.
5. In compliance with the provisions of Sections 108 and 110 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company provides the Members the facility to exercise their right to vote by electronic means through e-voting services provided by NSDL and the business may be transacted through such voting. The instructions for e-voting are annexed to this Notice.
6. The e-voting period shall commence on **Friday, 28th August, 2026 at 09.00 A.M. (IST)** and end on **Saturday, 26th September, 2026 at 05.00 P.M. (IST**). E-voting shall not be allowed beyond the said date and time.
7. The voting rights of Members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date i.e., **Friday, 21st August, 2026**.
8. Once the vote on the resolution is cast by the Members, the Members shall not be allowed to change it subsequently.
9. The Board of Directors of the Company ("**the Board**"), has appointed **Mrs. Rupal Patel, Practicing Company Secretary** (COP.: 3803) as the Scrutinizer, for conducting the e-voting process in a fair and transparent manner.
10. The Scrutinizer will submit her report to the Chairman or any other person authorized by the Chairman after the completion of scrutiny of the e-voting, and the result of the e-voting by Postal Ballot will be announced not later than 2 working days or 3 days, whichever is earlier from the conclusion of e-voting and will also be displayed on the Company website www.shukrapharmaceuticals.com, on the website of NSDL www.evoting.nsdl.com, and communicated to the stock exchange i.e. BSE Limited, NSE Limited and RTA.
11. The resolution, if passed by the requisite majority through Postal Ballot, will be deemed to have been passed on the last date specified for voting i.e. **Saturday, 26th September, 2026** Further, resolution passed by the members through postal ballot are deemed to have been passed as if they are passed at a General Meeting of the Members.
12. All material documents referred to in the explanatory statement will be available for inspection at the Registered Office of the Company during office hours on all working days from the date of dispatch until the last date for receipt of votes by e-voting. Alternately, Members may also send their requests to info@shukrapharmaceuticals.com in from their registered e-mail address mentioning their names, folio numbers, DP ID and Client ID during the voting period of the postal ballot.
13. Members may send an email request to support@purvashare.com, along with the scanned copy of their request letter duly signed by the Member (first member if held jointly), providing the email address, mobile number, self- attested copy of PAN and client master copy in case shares are held in electronic form or copy of the share certificate in case shares are held in physical form, to enable RTA to temporarily register their email address and mobile number. However, Members holding shares in electronic form, will have to once again register their email address and mobile number with their DPs, to permanently update the said information. In case of any queries, in this regard, Members are requested to write to support@purvashare.com or contact RTA at – 22-2301 2518 / 6761.
14. We urge Members to support our commitment to environmental protection by choosing to receive the Company's communication through email. Members holding shares in Demat mode, who have not registered their email addresses are requested to register their email addresses with their respective DP, and Members holding shares in physical mode are requested to update their email addresses with the Company's RTA at support@purvashare.com. Members may follow the process detailed below for registration of email ID:

Type of Holder	Process to be followed	
Physical	For availing the following investor services, send a written request in the prescribed forms to the RTA of the Company, Purva Sharegistry (India) Private Limited either by email to support@purvashare.com post to Unit no. 9, Shiv Shakti Ind. Estt., J .R. Boricha marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai 400011.	
	Form for availing investor services to register PAN, email address, bank details and other KYC details or changes / update thereof for securities held in physical mode	Form ISR - 1
	Update of signature of securities holder	Form ISR – 2
	For nomination as provided in the Rules 19 (1) of Companies (Share Capital and Debentures) Rules, 2014	Form ISR – 13
	Declaration to opt out	Form ISR – 3
	Cancellation of nomination by the holder(s) (along with ISR-3) / Change of Nominee	Form SH-14
	Form for requesting issue of duplicate Certificate and other service requests for shares / debentures / bonds, etc., held in physical form	Form ISR – 4
	The forms for updating the above details are available at www.shukrapharmaceuticals.com	
Demat	Please contact your DP and register your email address and bank account details in your demat account, as per the process advised by your DP.	

15. The Postal Ballot Notice and supporting documents are uploaded on the website of the Company, i.e. www.shukrapharmaceuticals.com and can also be accessed from the website of the BSE at www.bseindia.com , NSE at www.nseindia.com respectively. The Postal Ballot Notice is also disseminated on the website of NSDL, i.e., www.evoting.nsdl.com.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 2. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You

	will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 4. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on App Store Google Play
Individual Shareholders holding securities in demat mode with CDSL	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digits client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
      (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password**?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password**?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to roopalcs2001p@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on **"Upload Board Resolution / Authority Letter"** displayed under **"e-Voting"** tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on : 022 - 4886 7000 or send a request at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to www.shukrapharmaceuticals.com.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to (www.shukrapharmaceuticals.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in demat mode.
3. Alternatively, shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

16. SEBI has mandated the submission of PAN, KYC details and nomination by holders of physical securities by September 30, 2023 vide its circulars dated November 3, 2021, December 14, 2021 and March 16, 2023. It is also mandatory to link PAN with Aadhaar. Shareholders are requested to submit their PAN, KYC and nomination details to the Company's registrars Purva Sharegistry (India) Pvt. Ltd. at suuport@purvashare.com.
17. Members holding shares in electronic form are therefore, requested to submit their PAN to their depository participant(s). In case a holder of physical securities fails to furnish these details or link their PAN with Aadhaar before the due date, RTA is obligated to freeze such folios. The securities in the frozen folios shall be eligible to receive payments (including dividend) and lodge grievances only after furnishing the complete documents. If the securities continue to remain frozen as on January 31, 2026, the RTA / the Company shall refer such securities to the administering authority under the Benami Transactions (Prohibitions) Act, 1988, and / or the Prevention of Money Laundering Act, 2002.
18. Pursuant to Regulation 40 of Listing Regulations, as amended, securities of Listed Companies can be transferred only in dematerialized form with effect from April 1, 2019, except in case of transmission or transposition of securities. Further, SEBI vide its circular no. SEBI/HO/MIRSD/RTAMB/CIR/P/2020/236 dated December 02, 2020 had fixed March 31, 2021 as the last date for re-lodgement of transfer deeds and the shares that are re-lodged for transfer shall be issued only in demat mode. SEBI vide its notification dated January 24, 2022 has mandated that all requests for transfer of securities including transmission or transposition of securities shall be processed only in dematerialized form. Shareholders can contact the Company or Company's RTA for any assistance in this regard.

Date: 22/08/2026
Place: Ahmedabad

By the order of the Board
For Shukra Pharmaceuticals Limited

Registered office:
3rd Floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, 380054
CIN: L24231-GJ1993PLC019079
E-mail: info@shukrapharmaceuticals.com
Website: www.shukrapharmaceuticals.com

Sd/-
Dakshesh Shah
Chairman & Managing Director
DIN: 00561666

EXPLANATORY STATEMENT

(Statement pursuant to Section 102 of the Companies Act, 2013)

The following is the statement setting out the material facts relating to the Special Business mentioned in the accompanying notice dated August 22, 2026 and shall be taken as forming part of the Notice.

ITEM NO. 1: ALTERATION OF OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

The Company is presently engaged in the business as set out in its existing Memorandum of Association ("MOA"). In the course of its business operations and while exploring opportunities for future growth and diversification, the Company has identified Medical Technology ("MedTech") and healthcare technology as a promising and strategically important business vertical.

The Company has been receiving encouraging business interest and market response in the MedTech sector and has been developing meaningful business relationships with various parties in this sector. The Company has, inter alia, been receiving business enquiries, opportunities for strategic tie-ups, Memoranda of Understanding ("MOUs"), collaborations and other potential arrangements relating to medical technology devices, healthcare equipment, medical devices and allied healthcare technology solutions.

These developments have encouraged the management to evaluate the MedTech sector as a potential growth vertical for the Company. The healthcare and medical technology industry is undergoing significant technological advancement, with increasing adoption of medical devices, diagnostic equipment, robotic and AI-enabled healthcare solutions, digital healthcare platforms, hospital automation and other technology-driven healthcare solutions.

In view of the opportunities emerging in this sector and the Company's increasing engagement with potential business partners, the Board of Directors is of the view that entering into and developing a Medical Technology and Healthcare Technology vertical would provide the Company with an opportunity to diversify its business activities, broaden its revenue base and explore new avenues of growth.

Accordingly, the Company proposes to expand the scope of its main objects to enable it to undertake activities relating to research, innovation, design, development and manufacturing of medical devices and medical equipment; diagnostic systems, surgical instruments and robotic surgical systems; wearable healthcare devices and implantable devices; artificial intelligence-based healthcare technologies and digital healthcare solutions; healthcare software, telemedicine and hospital automation solutions; import, export, distribution, marketing and commercialisation of medical technology products; strategic alliances, collaborations, joint ventures, technology transfer and OEM arrangements; establishment and operation of research laboratories, manufacturing facilities, testing centres, incubation centres and other allied infrastructure; and installation, commissioning, maintenance, repair, calibration, technical support, training and other allied services relating to MedTech products and solutions.

The proposed alteration of the Object Clause is therefore intended to provide the Company with the necessary corporate and legal framework to pursue opportunities in the MedTech and healthcare technology sector and to enter into suitable arrangements with domestic and international companies, manufacturers, technology providers, research organisations, hospitals, institutions and other stakeholders.

The proposed objects are drafted broadly enough to enable the Company to undertake the complete lifecycle of MedTech products and solutions, including research and development, technology acquisition, manufacturing, assembly, testing, validation, installation, marketing, distribution, licensing, maintenance and commercialisation, either independently or through strategic collaborations, joint ventures, licensing arrangements, OEM arrangements or other suitable business structures.

The proposed alteration will also enable the Company to respond more effectively to business opportunities arising from the MOUs, proposed tie-ups, strategic discussions and other potential collaborations being explored in the MedTech sector. The proposed addition of the objects does not by itself constitute commencement of any specific new business activity or guarantee any particular revenue or profitability. Actual commencement of individual activities will be undertaken based on commercial viability, regulatory requirements, availability of resources and necessary approvals, wherever applicable.

The proposed expansion is expected to provide the Company with greater flexibility to:

1. diversify its existing business activities and revenue streams;
2. participate in the growing medical technology and healthcare technology ecosystem;
3. leverage opportunities arising from its existing and proposed business relationships and strategic tie-ups;
4. enter into technology collaborations and strategic partnerships with domestic and international players;
5. develop, manufacture, market and commercialise innovative medical technology products and solutions;
6. establish an integrated MedTech business encompassing products, technology and allied services;
7. explore opportunities in the areas of AI-enabled healthcare, digital health, diagnostics, robotic surgery and hospital automation; and
8. create long-term value for the Company and its stakeholders by developing an additional technology-oriented business vertical.

The Board believes that the proposed expansion is in the best interests of the Company and its Members, as it would enable the Company to explore emerging business opportunities, diversify its operations and build an additional growth-oriented business vertical while leveraging the business relationships and opportunities being developed by the Company in the MedTech sector.

Accordingly, the Board of Directors, at its meeting held on 22nd August, 2026, considered and approved the proposal for alteration of the Object Clause of the MOA, subject to the approval of the Members by way of Special Resolution and such other approvals as may be required under applicable laws.

The proposed alteration of the MOA requires the approval of the Members by way of a Special Resolution pursuant to Section 13 of the Companies Act, 2013, and other applicable provisions thereof. The proposed new objects are set out in full in the Special Resolution forming part of this Notice.

A copy of the existing Memorandum and Articles of Association of the Company and the proposed altered Memorandum of Association, together with the relevant documents referred to in this Notice, shall be available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of the meeting and shall also be made available electronically to the Members upon request in accordance with applicable provisions.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the proposed Special Resolution, except to the extent of their respective shareholding, if any, in the Company.

The Board recommends the Special Resolution set out at **Item No. 1** of the accompanying Notice for approval of the Members.

ITEM NO. 2: CHANGE OF NAME OF THE COMPANY FROM "SHUKRA PHARMACEUTICALS LIMITED" TO "SHUKRA MEDTECH LIMITED" AND CONSEQUENTIAL ALTERATION OF THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

The Company has, over the course of its business operations, been evaluating opportunities for expansion and diversification into new and emerging areas within the broader healthcare sector. In recent times, the Company has received encouraging business interest and has developed various business relationships, strategic connections, Memorandum of Understanding ("MOUs"), proposed collaborations and tie-ups in the field of Medical Technology ("MedTech") and healthcare technology.

The Company has identified the MedTech sector as a significant potential growth opportunity and proposes to develop this vertical as an important part of its future business strategy. The proposed expansion includes opportunities relating to medical devices, medical equipment, diagnostic systems, surgical and robotic systems, healthcare technology, digital healthcare solutions, artificial intelligence-based healthcare applications, hospital automation and other allied MedTech products and services.

In view of the Company's proposed expansion into the MedTech and healthcare technology sector, the existing name "Shukra Pharmaceuticals Limited" may no longer adequately represent the broader scope and future direction of the Company's business.

Accordingly, the Board of Directors is of the view that the proposed change of name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited" would more appropriately reflect the Company's proposed business activities, strategic direction and its intention to establish and develop a broader healthcare and medical technology-oriented business platform.

The proposed name "Shukra Medtech Limited" is intended to provide the Company with a broader corporate identity corresponding to its proposed expansion beyond the traditional pharmaceutical business into the wider healthcare and MedTech ecosystem. The proposed name is also expected to provide greater alignment between the Company's corporate identity and the products, technologies, collaborations and business opportunities that the Company proposes to pursue.
The proposed change of name is therefore being undertaken with the following broad objectives:

1. To align the corporate identity of the Company with its proposed business strategy and future growth plans;
2. To reflect the Company's proposed expansion into Medical Technology and allied healthcare technology businesses;
3. To provide a broader identity for undertaking activities relating to medical devices, healthcare equipment, diagnostic systems, digital healthcare and other MedTech solutions;
4. To facilitate strategic collaborations, MOUs, technology tie-ups, OEM arrangements, joint ventures, licensing arrangements and other business relationships in the MedTech sector;
5. To create a distinct and appropriate identity for the Company's proposed MedTech vertical in the domestic and international markets; and
6. To enable the Company to pursue diversified opportunities in the healthcare and technology sectors and create sustainable long-term value for its stakeholders.

The proposed change of name is also consistent with the proposed alteration of the Object Clause of the Memorandum of Association, as set out under Item No. 1 of the accompanying Notice, whereby the Company proposes to include various activities relating to Medical Technology, healthcare technology, medical devices, healthcare software, digital healthcare, artificial intelligence-based healthcare solutions and allied activities.

The Board believes that the proposed name "Shukra Medtech Limited" would better represent the Company's proposed diversified business profile and would provide a suitable platform for the Company to develop its existing and proposed business opportunities in the MedTech sector.

The change of name will not affect the identity, legal status, rights, obligations, liabilities or continuity of the Company. All contracts, agreements, arrangements, licences, permissions, proceedings, assets, liabilities, rights and obligations of the Company shall continue unaffected notwithstanding the change of name.

The Name is available by the Ministry of Corporate Affairs vide Letter dated 14th August, 2026. The Board of Directors, at its meeting held on 22nd August, 2026, considered and approved the proposal for change of name of the Company from **“Shukra Pharmaceuticals Limited” to “Shukra Medtech Limited”**, subject to the approval of the Members and the requisite statutory and regulatory approvals.

Consequent upon the change of name becoming effective, Clause I of the Memorandum of Association relating to the name of the Company shall be altered accordingly. The Articles of Association of the Company will also be altered to substitute the existing name of the Company wherever appearing therein with the new name.

Further, in compliance with Regulation 45(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has obtained a certificate from a Practicing Chartered Accountant confirming compliance with the conditions prescribed under the said regulation 45(1). Accordingly, a certificate issued by a Practicing Chartered Accountant is annexed hereto as Annexure–A and is also available on the Company’s website at www.shukrapharmaceuticals.com.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the proposed Special Resolution, except to the extent of their respective shareholding, if any, in the Company.

A copy of the existing Memorandum and Articles of Association of the Company, the proposed altered Memorandum and Articles of Association and other relevant documents relating to the proposed change of name shall be available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of the meeting. The same shall also be made available electronically to the Members upon request in accordance with applicable provisions.

The Board of Directors recommends the **Special Resolution set out at Item No. 2** of the accompanying Notice for approval of the Members.

Date: 22/08/2026
Place: Ahmedabad

By the order of the Board
For Shukra Pharmaceuticals Limited

Registered office:
3rd Floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, 380054
CIN: L24231-GJ1993PLC019079
E-mail: info@shukrapharmaceuticals.com
Website: www.shukrapharmaceuticals.com

Sd/-
Dakshesh Shah
Chairman & Managing Director
DIN: 00561666

Independent Auditor's Certificate under Regulation 45 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of directors,
Shukra Pharmaceuticals Limited
3rd Floor, Dev House,
Opp. WIAA, Judges Bungalows Road, Bodakdev,
Ahmedabad-380054.

1. This certificate is issued in accordance with the communication dated August 21, 2026 with Shukra Pharmaceuticals Limited (hereinafter referred to as the "Company").

2. We have been requested by the Company to certify that the Company has complied with conditions as specified under Sub-Regulation (1) of Regulation 45 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Regulation') with respect to proposed change in the name of the Company from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited".

Management's Responsibility

3. The management of the Company is responsible for the preparation and maintenance of all accounting and other records and documents supporting the particulars as mentioned in this certificate. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the required details and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

4. The Management is also responsible for ensuring that the Company complies with the conditions specified under Sub-Regulation (1) of Regulation 45 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Regulation') and relevant provision of the Companies Act 2013 (the "Act") for proposed change in the name of the Company.

Auditor's Responsibility

5. Our responsibility is to provide a reasonable assurance that the Company has complied with the conditions as specified under Sub-Regulation (1) of Regulation 45 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Regulation') for proposed change in the name of the Company from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited".

6. For the purpose of this certificate, we have relied on following:

   a) Copy of signed Board resolution dated May 7,2026 provided by the Company
   b) Books of Accounts for the period from July 1, 2025 to June 30, 2026
   c) Latest Unaudited Financials results for quarter ended June 30, 2026
   d) Management representation provided by the Company.

7. We conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

8. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

Opinion

9. Based on the information and explanations given to us and verification of the records and documents of the Company, we hereby certify that the Company is in compliance with the following conditions as specified in regulation 45(1) of SEBI (LODR):

Regulation	**Particulars**	**Remarks**
45(1)(a)	Time period of at least one year has elapsed from the last name change	The Company has not changed its name during the preceding one-year period. Accordingly, the requirement under Regulation 45(1)(a) is satisfied.
45(1)(b)	At least fifty percent of the total revenue in the preceding year period has been accounted for by the new activity suggested by the new name	No revenue has been generated from the new activity suggested by the proposed new name during the preceding year. Accordingly, the requirement of at least 50% of total revenue under Regulation 45(1)(b) is not satisfied.
45(1)(c)	The amount invested in the new activity/project is at least fifty percent. of the assets of the listed entity	The amount invested in the new activity/project suggested by the proposed new name is more than 50% of the total assets of the Company. Accordingly, the requirement under Regulation 45(1)(c) is satisfied.

This certificate is prepared based on the books and documents/records produced before us for verification and relied upon and on the request of the management of the Company for onward submission.

Restriction on Use

10. The certificate is addressed to and provided to the Board of Directors of the entity solely for the purpose to include it in explanatory statement of the Notice of the General Meeting and any intimation to the Stock Exchange. This Certificate should not be used for any other purpose or by any person other than the addressee of this Certificate. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this Certificate is shown or into whose hands it may come without our prior consent in writing.

For, Shah Sanghvi & Associates,
Chartered Accountants
Firm Registration No.: 140107W

Sd/-
Ravi Shah
Partner
Membership no: 149091

Date: August 27, 2026
Place: Ahmedabad
UDIN: 26149091HTHHZB4911